NASDAQ$KRYS
Krystal Biotech Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
Krystal Biotech reported Q4 net product revenue of $42.1 million from VYJUVEK sales and a net income of $8.7 million. The company closed the year with a strong balance sheet, holding $594.1 million in cash and investments.
- Net product revenue reached $42.1 million in Q4 and $50.7 million for the year.
- New England Journal of Medicine published data on the use of B-VEC eyedrop formulation.
- Alignment with FDA was reached to enable approval of B-VEC eyedrop formulation for treating lesions in the eye of DEB patients.
- First patient dosed in Phase 1 KB408 trial for AATD treatment, with five active clinical trials planned for 2024.
Headline financials
Revenue & EPS history
Krystal Biotech · Revenue · Quarterly
$42.1M
Revenue by segment
Krystal Biotech · $91.1M total across 1 segment · Q4 2024
- VYJUVEK Net Product Revenue$91.1M—100.0%
Forward guidance
Krystal Biotech provided financial guidance for the full year 2024.
Tailwinds
- Expects to expand VYJUVEK access in the U.S. and globally.
- Anticipates potential B-VEC approval for DEB treatment in the EU in 2H 2024.
- Intends to file a Japanese New Drug Application for B-VEC in 2H 2024.
- Plans to announce interim data from its Phase 1 study of KB408 in 2H 2024.
- Plans to initiate a study in 2H 2024 of B-VEC eyedrops for treating lesions in the eye of DEB patients.
Headwinds
- Uncertainties associated with regulatory review of clinical trials and applications for marketing approvals.
- The availability or commercial potential of VYJUVEK or product candidates.
- The sufficiency of cash resources and need for additional financing.
- Combined R&D and SG&A expense guidance does not include stock-based compensation.
- The company is unable to confidently estimate Full Year 2024 stock-based compensation expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.3%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+9.5%
Avg return
30 days after
54%
19 / 35 earnings
Positive
+52.8%
Q4 2023
Best reaction
-14.0%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +14.9% | +13.3% | |
| Q4 2025 | +4.0% | -5.3% | -6.7% | |
| Q3 2025 | +4.9% | +0.2% | +10.1% | |
| Q2 2025 | -14.0% | -11.7% | -4.3% | |
| Q1 2025 | -13.8% | -18.6% | -18.3% | |
| Q4 2024 | +12.4% | +19.3% | +19.4% | |
| Q3 2024 | -1.1% | +13.2% | +6.4% | |
| Q2 2024 | -6.9% | -5.1% | -3.1% | |
| Q1 2024 | +0.4% | -3.9% | +4.1% | |
| Q4 2023 | +52.8% | +50.7% | +59.2% | |
| Q3 2023 | -10.7% | -19.3% | -16.1% | |
| Q2 2023 | -6.7% | -4.2% | -0.2% | |
| Q1 2023 | +9.0% | +4.7% | +51.2% | |
| Q4 2022 | +4.4% | +0.7% | +2.0% | |
| Q3 2022 | +7.7% | +4.7% | +1.6% | |
| Q2 2022 | -5.2% | -3.4% | -17.1% | |
| Q1 2022 | -4.7% | +0.4% | +15.4% | |
| Q4 2021 | +2.6% | -8.2% | +7.0% | |
| Q3 2021 | -7.4% | -7.4% | +48.5% | |
| Q2 2021 | -1.6% | -6.2% | -3.2% | |
| Q1 2021 | -7.2% | -4.0% | -7.6% | |
| Q4 2020 | +6.8% | -7.8% | -2.3% | |
| Q3 2020 | +2.6% | +3.1% | +35.0% | |
| Q2 2020 | +0.5% | +6.7% | +11.7% | |
| Q1 2020 | +13.7% | +25.3% | +3.8% | |
| Q4 2019 | -0.7% | -12.0% | -12.0% | |
| Q3 2019 | +1.6% | +0.5% | +43.5% | |
| Q2 2019 | -4.0% | -3.3% | -6.2% | |
| Q1 2019 | +2.6% | +14.6% | +1.1% | |
| Q4 2018 | -4.1% | +1.9% | +55.6% | |
| Q3 2018 | -4.7% | -1.5% | +5.4% | |
| Q2 2018 | +2.7% | +1.5% | +6.1% | |
| Q1 2018 | +0.1% | +0.2% | +23.5% | |
| Q4 2017 | +5.8% | +21.2% | +2.9% | |
| Q3 2017 | +6.0% | +1.9% | +4.1% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro